Search｜Photos & Images & Videos｜KYODO NEWS IMAGES INC

Illustration Simcere

SUQIAN, CHINA - AUGUST 12, 2024 - Illustration Simcere, an antiviral drug for COVID-19, in Suqian, Jiangsu province, China, August 12, 2024.

E

Illustration Simcere

SUQIAN, CHINA - AUGUST 12, 2024 - Illustration Simcere, an antiviral drug for COVID-19, in Suqian, Jiangsu province, China, August 12, 2024.

E

Illustration Simcere

SUQIAN, CHINA - AUGUST 12, 2024 - Illustration Simcere, an antiviral drug for COVID-19, in Suqian, Jiangsu province, China, August 12, 2024.

E

Illustration Simcere

SUQIAN, CHINA - AUGUST 12, 2024 - Illustration Simcere, an antiviral drug for COVID-19, in Suqian, Jiangsu province, China, August 12, 2024.

E

Illustration Simcere

SUQIAN, CHINA - AUGUST 12, 2024 - Illustration Simcere, an antiviral drug for COVID-19, in Suqian, Jiangsu province, China, August 12, 2024.

E

Japan professor awarded for AIDS treatment findings

KAGOSHIMA, Japan - Photo taken May 20, 2013, shows Masanori Baba, a professor at Kagoshima University in Kagoshima City, Kagoshima Prefecture, who won an award from the Washington-based International Society for Antiviral Research earlier that month for his discovery of two candidate substances for anti-AIDS drugs.

E

Malaysia drops indoor face mask mandate

STORY: Malaysia drops indoor face mask mandate DATELINE: Sept. 8, 2022 LENGTH: 00:01:12 LOCATION: Kuala Lumpur CATEGORY: SOCIETY SHOTLIST: 1. shot of Kuala Lumpur Twin Towers with Malaysia's National Flag 2. various of crowds indoors STORYLINE: Malaysia has dropped the mandatory use of face masks for indoor spaces, Health Minister Khairy Jamaluddin announced on Wednesday. The discretion on whether masks should be worn indoors will be left to the owners of premises, with owners who wished to impose the wearing of face masks being allowed to do so, Khairy told a press conference. "It's the owners' right to deny customers who flout their conditions. Some premises owners might feel that they are exposed and the risk is high if masks are not worn," Khairy said. The decision was made due to the easing COVID-19 situation in the country and the greater availability of antiviral medication but other measures would remain in place to prevent the spread of the disease, Khairy added. The wearing of face masks rema

E

Covid Antiviral Pill Can Halve Risk Of Hospitalisation

Handout - An experimental drug for severe Covid cuts the risk of hospitalisation or death by about half, interim clinical trial results suggest. The tablet - molnupiravir - was given twice a day to patients recently diagnosed with the disease. US drug-maker Merck said its results were so positive that outside monitors had asked to stop the trial early. It said it would apply for emergency use authorisation for the drug in the US in the next two weeks. Dr Anthony Fauci, chief medical adviser to US President Joe Biden, said the results were "very good news", but urged caution until the US Food and Drug Administration (FDA) had reviewed the data. Photo courtesy of Merck Sharp & Dohme Corp via ABACAPRESS.COM

E

Covid Antiviral Pill Can Halve Risk Of Hospitalisation

Handout - An experimental drug for severe Covid cuts the risk of hospitalisation or death by about half, interim clinical trial results suggest. The tablet - molnupiravir - was given twice a day to patients recently diagnosed with the disease. US drug-maker Merck said its results were so positive that outside monitors had asked to stop the trial early. It said it would apply for emergency use authorisation for the drug in the US in the next two weeks. Dr Anthony Fauci, chief medical adviser to US President Joe Biden, said the results were "very good news", but urged caution until the US Food and Drug Administration (FDA) had reviewed the data. Photo courtesy of Merck Sharp & Dohme Corp via ABACAPRESS.COM

E

Covid Antiviral Pill Can Halve Risk Of Hospitalisation

Handout - An experimental drug for severe Covid cuts the risk of hospitalisation or death by about half, interim clinical trial results suggest. The tablet - molnupiravir - was given twice a day to patients recently diagnosed with the disease. US drug-maker Merck said its results were so positive that outside monitors had asked to stop the trial early. It said it would apply for emergency use authorisation for the drug in the US in the next two weeks. Dr Anthony Fauci, chief medical adviser to US President Joe Biden, said the results were "very good news", but urged caution until the US Food and Drug Administration (FDA) had reviewed the data. Photo courtesy of Merck Sharp & Dohme Corp via ABACAPRESS.COM

E

Copper fiber sheet commercialized by Good Eye

Good Eye (Kiryu City, Gunma Prefecture) will release GUD Sheet, a copper fiber sheet with antibacterial and antiviral effects, in June. The company commercialized four types of masks, including one priced at 4,980 yen (excluding consumption tax). The GUD sheet is a polymer fiber covered with copper foil and coated with a visible light responsive photocatalyst. In an experiment on bacteriophage, a virus that infects bacteria, it was confirmed that rubbing a finger covered with the virus on the sheet for 30 seconds reduced the number of the virus to less than 1/1000.Professor Hideyuki Itabashi of the Graduate School of Science and Engineering, Gunma University, who also serves as the company's chairman, said, "We hope to start experiments in July. The photo shows copper fiber sheets commercialized as masks and chiefs. (Photo taken on May 19, 2020, location unknown, credit: Nikkan Kogyo Shimbun / Kyodo News Images)

E

In-train spraying of antiviral materials by JR West

West Japan Railway Co. (JR West) has begun anti-viral and anti-bacterial treatment of the entire interior of its trains, with plans to implement the treatment on about 3,600 cars running in the Keihanshin area by the end of September and eventually on all 5,200 cars on conventional lines. The plan is to ensure the safety and security of passengers under with corona. The system uses chemicals that have been confirmed by a third-party organization to be effective against influenza and noroviruses. The effect will last for several years, the company said. The chemicals will be sprayed on windows, seats and other places where passengers may touch them. The number of commuters and other passengers in the Kansai region is gradually returning following the lifting of the state of emergency declared for the new coronavirus infection on March 21. Kazuaki Hasegawa, president of the company, said, Photo taken on May 22, 2020, location unknown, credit: Nikkan Kogyo Shimbun / Kyodo News Images

E

Remdesivir, Veklury, drugs, syringe.

Experimental antiviral drug for COVID-19 Remdesivir, in Prague, Czech Republic, April 5, 2021. (CTK Photo/Martin Macak Gregor)

E

Remdesivir, Veklury, drugs, syringe.

Experimental antiviral drug for COVID-19 Remdesivir, in Prague, Czech Republic, April 5, 2021. (CTK Photo/Martin Macak Gregor)

E

Remdesivir, Veklury, drugs, syringe.

Experimental antiviral drug for COVID-19 Remdesivir, in Prague, Czech Republic, April 5, 2021. (CTK Photo/Martin Macak Gregor)

E

Remdesivir, Veklury, drugs, syringe.

Experimental antiviral drug for COVID-19 Remdesivir, in Prague, Czech Republic, April 5, 2021. (CTK Photo/Martin Macak Gregor)

E

Remdesivir, Veklury, drugs, syringe, hands in gloves.

Experimental antiviral drug for COVID-19 Remdesivir, in Prague, Czech Republic, April 5, 2021. (CTK Photo/Martin Macak Gregor)

E

Remdesivir, Veklury, drugs, syringe, hands in gloves.

Experimental antiviral drug for COVID-19 Remdesivir, in Prague, Czech Republic, April 5, 2021. (CTK Photo/Martin Macak Gregor)

E

Remdesivir, Velkury, drugs, sign, box

Experimental antiviral drug for COVID-19 Remdesivir, in Prague, Czech Republic, April 5, 2021. (CTK Photo/Martin Macak Gregor)

E

Remdesivir, Veklury, drugs, syringe, hands in gloves.

Experimental antiviral drug for COVID-19 Remdesivir, in Prague, Czech Republic, April 5, 2021. (CTK Photo/Martin Macak Gregor)

E

Remdesivir, Veklury, drugs, syringe, hands in gloves.

Experimental antiviral drug for COVID-19 Remdesivir, in Prague, Czech Republic, April 5, 2021. (CTK Photo/Martin Macak Gregor)

E

Favipiravir, drugs, box, unregistered drug, hands in gloves.

Experimental Japanese antiviral drug for COVID-19 Favipiravir, in Prague, Czech Republic, April 5, 2021. (CTK Photo/Martin Macak Gregor)

E

Remdesivir, Veklury, drugs, syringe, hands in gloves.

Experimental antiviral drug for COVID-19 Remdesivir, in Prague, Czech Republic, April 5, 2021. (CTK Photo/Martin Macak Gregor)

E

Remdesivir, Veklury, drugs, syringe, hands in gloves.

Experimental antiviral drug for COVID-19 Remdesivir, in Prague, Czech Republic, April 5, 2021. (CTK Photo/Martin Macak Gregor)

E

Remdesivir, Veklury, drugs, syringe, hands in gloves.

Experimental antiviral drug for COVID-19 Remdesivir, in Prague, Czech Republic, April 5, 2021. (CTK Photo/Martin Macak Gregor)

E

Remdesivir, Veklury, drugs, syringe, hands in gloves.

Experimental antiviral drug for COVID-19 Remdesivir, in Prague, Czech Republic, April 5, 2021. (CTK Photo/Martin Macak Gregor)

E

Remdesivir, Veklury, drugs, syringe, hands in gloves.

Experimental antiviral drug for COVID-19 Remdesivir, in Prague, Czech Republic, April 5, 2021. (CTK Photo/Martin Macak Gregor)

E

Favipiravir, drugs, box, unregistered drug, hands in gloves.

Experimental Japanese antiviral drug for COVID-19 Favipiravir, in Prague, Czech Republic, April 5, 2021. (CTK Photo/Martin Macak Gregor)

E

Favipiravir, drugs, box, unregistered drug, hands in gloves.

Experimental Japanese antiviral drug for COVID-19 Favipiravir, in Prague, Czech Republic, April 5, 2021. (CTK Photo/Martin Macak Gregor)

E

Remdesivir, Veklury, drugs, syringe, hands in gloves.

Experimental antiviral drug for COVID-19 Remdesivir, in Prague, Czech Republic, April 5, 2021. (CTK Photo/Martin Macak Gregor)

E

Remdesivir, Veklury, drugs, syringe, hands in gloves.

Experimental antiviral drug for COVID-19 Remdesivir, in Prague, Czech Republic, April 5, 2021. (CTK Photo/Martin Macak Gregor)

E

Remdesivir, Veklury, drugs, syringe, hands in gloves.

Experimental antiviral drug for COVID-19 Remdesivir, in Prague, Czech Republic, April 5, 2021. (CTK Photo/Martin Macak Gregor)

E

Remdesivir, Veklury, drugs, syringe, hands in gloves.

Experimental antiviral drug for COVID-19 Remdesivir, in Prague, Czech Republic, April 5, 2021. (CTK Photo/Martin Macak Gregor)

E

Favipiravir, drugs, box, unregistered drug, hands in gloves.

Experimental Japanese antiviral drug for COVID-19 Favipiravir, in Prague, Czech Republic, April 5, 2021. (CTK Photo/Martin Macak Gregor)

E

David Feltl

Director of the General Teaching Hospital in Prague David Feltl speaks during a press conference on coronavirus treatment, on March 24, 2020, in Prague, Czech Republic. The hospital received the remdesivir novel antiviral drug and it started administering it to a patient seriously ill with COVID-19. (CTK Photo/Ondrej Deml)

E

Martin Balik, David Feltl

Doctor Martin Balik, left, and director of the General Teaching Hospital in Prague David Feltl, right, speak during a press conference on coronavirus treatment, on March 24, 2020, in Prague, Czech Republic. The hospital received the remdesivir novel antiviral drug and it started administering it to a patient seriously ill with COVID-19. (CTK Photo/Ondrej Deml)

E

Martin Balik

Doctor Martin Balik of the General Teaching Hospital in Prague speaks during a press conference on coronavirus treatment, on March 24, 2020, in Prague, Czech Republic. The hospital received the remdesivir novel antiviral drug and it started administering it to a patient seriously ill with COVID-19. (CTK Photo/Ondrej Deml)

E

JANA ZIMOVA, owner, Company Respilon, face mask, with copper oxides

Respilon company gives press conference on new Virus Killer antiviral face mask in Brno, Czech Republic, March 17, 2020. (CTK Photo/Vaclav Salek)

E

JANA ZIMOVA, owner, Company Respilon, face mask, with copper oxides

Respilon company gives press conference on new Virus Killer antiviral face mask in Brno, Czech Republic, March 17, 2020. (CTK Photo/Vaclav Salek)

E

Company Respilon, face mask, with copper oxides

Respilon company gives press conference on new Virus Killer antiviral face mask in Brno, Czech Republic, March 17, 2020. (CTK Photo/Vaclav Salek)

E

JANA ZIMOVA, owner, Company Respilon, face mask, with copper oxides

Respilon company gives press conference on new Virus Killer antiviral face mask in Brno, Czech Republic, March 17, 2020. (CTK Photo/Vaclav Salek)

E

JANA ZIMOVA, owner, Company Respilon, face mask, with copper oxides

Respilon company gives press conference on new Virus Killer antiviral face mask in Brno, Czech Republic, March 17, 2020. (CTK Photo/Vaclav Salek)

E

JANA ZIMOVA, owner, Company Respilon, face mask, with copper oxides

Respilon company gives press conference on new Virus Killer antiviral face mask in Brno, Czech Republic, March 17, 2020. (CTK Photo/Vaclav Salek)

E

Company Respilon, face mask, with copper oxides

Respilon company gives press conference on new Virus Killer antiviral face mask in Brno, Czech Republic, March 17, 2020. (CTK Photo/Vaclav Salek)

E

Company Respilon, face mask, with copper oxides

Respilon company gives press conference on new Virus Killer antiviral face mask in Brno, Czech Republic, March 17, 2020. (CTK Photo/Vaclav Salek)

E

Tokyo stocks climb on new COVID-19 treatment hope

A financial data screen in Tokyo shows the Nikkei Stock Average (L) surging above the 20,000 mark on April 30, 2020, on reports that clinical trials of experimental antiviral drug remdesivir showed positive results in COVID-19 sufferers. (Kyodo) ==Kyodo

E

Tokyo stocks climb on new COVID-19 treatment hope

A financial data screen in Tokyo shows the Nikkei Stock Average surging above the 20,000 mark on April 30, 2020, on reports that clinical trials of experimental antiviral drug remdesivir showed positive results in COVID-19 sufferers. (Kyodo) ==Kyodo

E

Tokyo stocks climb on new COVID-19 treatment hope

A financial data screen in Tokyo shows the Nikkei Stock Average surging above the 20,000 mark on April 30, 2020, on reports that clinical trials of experimental antiviral drug remdesivir showed positive results in COVID-19 sufferers. (Kyodo) ==Kyodo

E

Tokyo stocks climb on new COVID-19 treatment hope

A financial data screen in Tokyo shows the Nikkei Stock Average surging above the 20,000 mark on April 30, 2020, on reports that clinical trials of experimental antiviral drug remdesivir showed positive results in COVID-19 sufferers. (Kyodo) ==Kyodo

E

Tokyo stocks climb on new COVID-19 treatment hope

A financial data screen in Tokyo shows the Nikkei Stock Average surging above the 20,000 mark on April 30, 2020, on reports that clinical trials of experimental antiviral drug remdesivir showed positive results in COVID-19 sufferers. (Kyodo) ==Kyodo